Insight
Multiplex Immunoassays for Idiopathic Pulmonary Fibrosis
Multiple peer-reviewed publications have consistently demonstrated a set of blood-based protein biomarkers associated with idiopathic pulmonary fibrosis (IPF) disease progression. A set of well-qualified assays suitable for use as prognostic or predictive biomarkers within the context for IPF clinical trials is lacking. In collaboration with the Prognostic Lung Fibrosis Consortium (PROLIFIC), IQVIA Laboratories Protein Biomarkers developed highly optimized and analytically validated blood-based proteomic assays for IPF on the Luminex® multi-analyte profile (MAP), specifically focusing on the most relevant IPF biomarkers related to epithelial damage, fibrosis, inflammation and thrombosis.
Complete the form to access this whitepaper
Related Insights
The End to End Importance of Selecting the Right Biomarker in Cancer Studies
A critical component in the fight against cancer and optimizing treatment outcomes for patients
IQVIA Laboratories Biomarker Services
Providing tools and experience to maximize your biomarker strategy
Biomarker roadmap to success
Develop a biomarker roadmap for a successful strategy in developing targeted therapies
Building a Best-in-Class Model for Global CDx Clinical Trial Deployment
11th Annual World Clinical Biomarkers & CDx Summit
Translational Science and Innovation Laboratory (TSAIL)
Translational biomarker solutions to accelerate the adoption of assays into clinical trials though new technology evaluation and early biomarker discovery
Alzheimer’s Disease Clinical Trials
Innovative laboratory solutions to accelerate progress
Selection of Biomarkers for Immuno-Oncology with Patrice Hugo
I-O clinical development podcast series
Biomarker-Driven Trials: How Laboratory Insight Can Enhance Clinical Trial Design and Optimize Drug Development
Diabetes Solutions
Learn how we support our customers across the development continuum in their fight against the global diabetes epidemic.
Next Generation Immuno-Oncology Flow Cytometry with Mark Edinger
I-O clinical development podcast series
